Previous Close | 2.7500 |
Open | 2.7200 |
Bid | 2.7100 x 2900 |
Ask | 2.7300 x 900 |
Day's Range | 2.6365 - 3.0683 |
52 Week Range | 1.7400 - 76.5000 |
Volume | |
Avg. Volume | 3,664,701 |
Market Cap | 10.825M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 0.21 |
EPS (TTM) | 13.1500 |
Earnings Date | Mar 16, 2023 - Mar 20, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for PALI
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.
Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company”), today announced that holders of an additional 1.46 million common stock purchase warrants issued pursuant to the Company’s August 2022 public offering (the “Warrants”) have exercised such War
Live video webcast on Tuesday, January 17th at 3:00 PM ET Carlsbad, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley, Interim Chief Executive Officer of Palisade Bio will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 3:00 PM ET. A live video webcast of the presentation will be a